NewsRoom Articles - BioMedWire (BMW)

WednesdayMar 04, 2026 9:45 am

Scaling Care, Tightening Controls: How Earth Science Tech Inc. (ETST) Is Building a Multi-Unit Healthcare Platform

Earth Science Tech reported fiscal Q3 2026 revenue of $8.4 million, up 14.1% year over year, with gross margin expanding to 76.3% and adjusted EBITDA rising to $1.2 million Management said Peaks, the company’s telemedicine platform, surpassed $2.0 million in revenue in less than a year, while the company pursues additional state licenses to expand its footprint ETST engaged Semple, Marchal and Cooper, LLP as its independent PCAOB auditor, a governance move framed as necessary as consolidated accounting complexity increases Healthcare delivery is being reshaped by two forces that often move at different speeds: consumer demand for faster access and…

TuesdayMar 03, 2026 10:00 am

New Treatment Dramatically Improves Survival for Patients with Deadly Brain Tumors

Researchers at Keck Medicine, University of Southern California (USC) have discovered that combining immunotherapy with laser heat therapy could significantly extend the survival of individuals diagnosed with deadly brain cancers. Astrocytoma, which includes cancers like glioblastoma, grows aggressively and usually recurs after patients have undergone surgery to remove the tumors. This makes the cancer difficult to treat, and patients rarely survive for more than 5 months once diagnosed with high-grade astrocytoma. Immunotherapies, treatments that leverage the body’s immune system to fight cancer, work remarkably well in addressing cancers found in other body parts. However, these treatments exhibit dismal results when used against brain cancers. This is because the blood-brain…

TuesdayMar 03, 2026 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Upgraded to Buy as New Joseph Gunnar Report Raises Price Target on Commercialization Momentum

New report upgrades HeartBeam to buy, raises 12-month price target to $4, citing regulatory progress and company’s transition toward commercialization. Joseph Gunnar characterized the FDA clearance of HeartBeam’s 12-lead ECG synthesis software for arrhythmia assessment as a “critical regulatory milestone.” The research report underscores the company’s targeted go-to-market strategy. Equity research reports often serve as important barometers of shifting sentiment, offering investors detailed analysis of a company’s strategy, risks and growth potential. In a new research note, Joseph Gunnar & Co. upgraded HeartBeam (NASDAQ: BEAT) from Hold to Buy and raised its 12-month price target to $4 from $1, citing…

MondayMar 02, 2026 9:00 am

Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy

There are several types of technologies for treating tumors with proton therapy, such as pencil beam scanning, passive scattering, and others Linac for Image Guided Hadron Therapy, LiGHT system, is believed to offer a more affordable, compact, and efficient design, along with better treatment precision than traditional technologies The system complements LIXTE’s lead clinical candidate, LB-100, which is a small-molecule PP2A inhibitor which is designed to enhance the activity of immunotherapy and chemotherapy Treating tumors with proton therapy is a highly advanced form of radiation that offers high precision, which minimizes radiation exposure for the tissue around the tumor. There…

FridayFeb 27, 2026 10:00 am

UCLA Researchers Develop Method to Fix Fuel Shortages in Cancer Immunotherapy

Many immunotherapies developed to combat cancer fail because the CAR-T cells become exhausted after being starved of oxygen in the tumor environment. A new preclinical study conducted by a team at UCLA has uncovered a method to deliver needed glucose to immune cells in a way that tumor cells cannot hijack. This offers hope of keeping anti-cancer fighter cells active and deadly to both solid and non-solid tumors. The study, whose findings appeared in Cell journal, documents how the researchers found a way to keep the oxygen supply of CAR-T cells intact in a way that cancer cells cannot steal and starve the immune cells. They…

ThursdayFeb 26, 2026 10:00 am

Medicare Advantage Insurers Record Slowing Growth in Member Enrollment

According to data released by the CMS last week, the expansion of people enrolled in Medicare Advantage (MA) plans has decelerated in 2026 to a degree that dwarfs what has been happening in recent years. The CMS data reveals that nearly 35.5 million individuals have so far enrolled for MA programs. This marks a paltry 3% growth of membership compared to last year which saw approximately 34.4 million individuals enroll for MA plans by this time of year. The 3% growth is a far cry from previous years that easily saw annual enrollment tick upwards by 10%. In recent years, the expansion of MA has continued to lose steam as many insurers withdraw from offering MA plans or scale down the number…

WednesdayFeb 25, 2026 9:00 am

Earth Science Tech Inc. (ETST) Accelerates Profitability and Governance Transformation, Signals 40% Net Income Growth Trajectory

ETST reported a third fiscal quarter 2026 revenue of $8.4 million, up 14.1% year-over-year Gross margin expanded to 76.3%, highlighting an improved operating leverage across its portfolio The company announced governance reforms and cost initiatives expected to drive about $1.4 million in annualized savings and over 40% projected net income growth Earth Science Tech (OTC: ETST), a strategic holding company reputed for acquiring and growing high-potential operating businesses, is stepping into a new era of disciplined growth characterized by expanding margins, optimizing cash generation, and a total shift toward a more shareholder-focused public company model. In the company’s third fiscal…

TuesdayFeb 24, 2026 10:00 am

American Science Suffers as Brain Drain Intensifies

The biomedical ecosystem in the U.S. is facing an unprecedented threat as younger researchers opt to work abroad amid the numerous challenges facing innovation within the United States. This brain drain particularly intensified starting last year when a number of policy changes left many with no option but to look for opportunities in other countries. For starters, thousands of grants have been slashed at the National Institutes of Health (NIH) and the National Science Foundation. Research projects at these institutions helped to absorb early career and entry-level scientists with new ideas that they studied using funding from the federal government. Without this vital entry point for young researchers, it is becoming extremely difficult for the country to maintain a…

MondayFeb 23, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care

LIXTE has acquired Liora Technologies Europe Ltd., securing its proprietary LiGHT system for advanced proton therapy treatment Liora works at the forefront of electronically controlled proton beam innovation, with its platform installed at the UK’s STFC Daresbury Laboratory These updates highlight LIXTE’s overarching mission to blend breakthrough drug development with transformative radiotherapy innovations in the global cancer fight Cancer is still one of the most widespread life-threatening diseases globally, with nearly all families affected either directly or as caregivers. Innovations in the medical ecosystem continue to gain momentum with the emergence of new immunotherapies, targeted drugs, and advanced radiation treatments.…

FridayFeb 20, 2026 10:00 am

Cancer Stress Protein Enables Tumors to Evade the Immune System

A study published this week has found that when cancer cells are stressed, they produce a certain protein that helps the cancer to avoid detection by the immune system. This discovery opens an opportunity for developing therapies that target this particular protein in order to make immunotherapy more effective against cancer. The study, which was conducted by a large team led by a group at New York University Langone Health, focused on pancreatic and lung cancer tumors. They studied the ISR (Integrated Stress Response) of the tumors. Tumor cells are constantly stressed because they multiply so fast and often lack all the nutrients they need to support their survival and further…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Scaling Care, Tightening Controls: How Earth Science Tech Inc. (ETST) Is Building a Multi-Unit Healthcare Platform

New Treatment Dramatically Improves Survival for Patients with Deadly Brain Tumors

HeartBeam Inc. (NASDAQ: BEAT) Upgraded to Buy as New Joseph Gunnar Report Raises Price Target on Commercialization Momentum

Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy

UCLA Researchers Develop Method to Fix Fuel Shortages in Cancer Immunotherapy

Medicare Advantage Insurers Record Slowing Growth in Member Enrollment

Earth Science Tech Inc. (ETST) Accelerates Profitability and Governance Transformation, Signals 40% Net Income Growth Trajectory

American Science Suffers as Brain Drain Intensifies

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care

Cancer Stress Protein Enables Tumors to Evade the Immune System

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search